JP2016506923A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506923A5 JP2016506923A5 JP2015554285A JP2015554285A JP2016506923A5 JP 2016506923 A5 JP2016506923 A5 JP 2016506923A5 JP 2015554285 A JP2015554285 A JP 2015554285A JP 2015554285 A JP2015554285 A JP 2015554285A JP 2016506923 A5 JP2016506923 A5 JP 2016506923A5
- Authority
- JP
- Japan
- Prior art keywords
- mir
- seq
- sequence
- nucleotide identity
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13305082.3A EP2759595B1 (en) | 2013-01-24 | 2013-01-24 | Composition comprising an encapsulated antagomir |
| EP13305082.3 | 2013-01-24 | ||
| PCT/IB2014/058500 WO2014115103A1 (en) | 2013-01-24 | 2014-01-23 | Composition comprising an encapsulated antagomir |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016506923A JP2016506923A (ja) | 2016-03-07 |
| JP2016506923A5 true JP2016506923A5 (enExample) | 2017-02-02 |
Family
ID=47683670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015554285A Pending JP2016506923A (ja) | 2013-01-24 | 2014-01-23 | カプセル化アンタゴｍｉｒを含む組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150352055A1 (enExample) |
| EP (2) | EP2759595B1 (enExample) |
| JP (1) | JP2016506923A (enExample) |
| KR (1) | KR20160018451A (enExample) |
| CN (1) | CN105229151A (enExample) |
| AU (1) | AU2014208419A1 (enExample) |
| BR (1) | BR112015017650A2 (enExample) |
| CA (1) | CA2898958A1 (enExample) |
| ES (2) | ES2606636T3 (enExample) |
| HK (1) | HK1219753A1 (enExample) |
| HU (1) | HUE032125T2 (enExample) |
| MX (1) | MX2015009323A (enExample) |
| PL (1) | PL2759595T3 (enExample) |
| RU (1) | RU2668794C2 (enExample) |
| WO (1) | WO2014115103A1 (enExample) |
| ZA (1) | ZA201505602B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2864482A4 (en) | 2012-06-21 | 2016-02-10 | Miragen Therapeutics Inc | OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN |
| HK1249108A1 (zh) * | 2015-01-20 | 2018-10-26 | 米拉根医疗股份有限公司 | Mir-92抑制剂及其用途 |
| EP3601565A4 (en) * | 2017-03-25 | 2021-01-06 | Miragen Therapeutics, Inc. | MIR-92 INHIBITORS IN THE TREATMENT OF HEART FAILURE |
| EP3939575B1 (en) * | 2019-03-14 | 2026-07-01 | M. Technique Co., Ltd. | PLGA MICROPARTICLES, DELAYED-RELEASE FORMULATION OF THESE AND THEIR MANUFACTURE PROCESS |
| CN110484537B (zh) * | 2019-09-02 | 2021-07-27 | 中国水产科学研究院淡水渔业研究中心 | 一种miR-92促进剂及其注射剂的制备方法和应用 |
| CN110804659B (zh) * | 2019-10-23 | 2023-02-03 | 华南农业大学 | 一种血清外泌体ssc-miR-92b-3p作为母猪早期妊娠诊断分子标志物的应用 |
| CN110917359A (zh) * | 2019-11-21 | 2020-03-27 | 武汉理工大学 | 离子键自组装制备PEG-P（Asp-AP）-ANTAGOMIR-RNA微球 |
| WO2021251526A1 (ko) * | 2020-06-11 | 2021-12-16 | 주식회사 프로스테믹스 | 신규한 mirna 유사체 및 이의 용도 |
| CN111729088B (zh) * | 2020-08-21 | 2020-12-15 | 江苏申基生物科技有限公司 | 一种微小核糖核酸miR-34a偶联探针及其制备方法 |
| WO2025050037A1 (en) * | 2023-08-31 | 2025-03-06 | The Regents Of The University Of Colorado, A Body Corporate | Microrna-15b antagomir and cerium oxide nanoparticles, and uses of same for treatment of intrauterine growth restriction |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7641643B2 (en) * | 2003-04-15 | 2010-01-05 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
| WO2005013901A2 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| DK2205737T3 (da) * | 2007-10-04 | 2013-05-21 | Santaris Pharma As | Mikromirer |
| DE102007052114B4 (de) * | 2007-10-30 | 2011-01-05 | T2Cure Gmbh | Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle |
| GB0814302D0 (en) * | 2008-08-05 | 2008-10-01 | Coretherapix Slu | Compounds and methods |
| KR20120047214A (ko) * | 2009-05-20 | 2012-05-11 | 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 | 심근경색 후 리모델링 및 심부전에 관련된 마이크로―ｒｎａ의 확인 |
-
2013
- 2013-01-24 ES ES13305082.3T patent/ES2606636T3/es active Active
- 2013-01-24 HU HUE13305082A patent/HUE032125T2/en unknown
- 2013-01-24 EP EP13305082.3A patent/EP2759595B1/en not_active Not-in-force
- 2013-01-24 PL PL13305082T patent/PL2759595T3/pl unknown
-
2014
- 2014-01-23 KR KR1020157022914A patent/KR20160018451A/ko not_active Withdrawn
- 2014-01-23 HK HK16107653.5A patent/HK1219753A1/zh unknown
- 2014-01-23 BR BR112015017650A patent/BR112015017650A2/pt not_active IP Right Cessation
- 2014-01-23 JP JP2015554285A patent/JP2016506923A/ja active Pending
- 2014-01-23 US US14/763,181 patent/US20150352055A1/en not_active Abandoned
- 2014-01-23 MX MX2015009323A patent/MX2015009323A/es unknown
- 2014-01-23 WO PCT/IB2014/058500 patent/WO2014115103A1/en not_active Ceased
- 2014-01-23 ES ES14706098.2T patent/ES2688160T3/es active Active
- 2014-01-23 EP EP14706098.2A patent/EP2948551B1/en not_active Not-in-force
- 2014-01-23 CN CN201480017728.3A patent/CN105229151A/zh active Pending
- 2014-01-23 RU RU2015134770A patent/RU2668794C2/ru not_active IP Right Cessation
- 2014-01-23 AU AU2014208419A patent/AU2014208419A1/en not_active Abandoned
- 2014-01-23 CA CA2898958A patent/CA2898958A1/en not_active Abandoned
-
2015
- 2015-08-04 ZA ZA2015/05602A patent/ZA201505602B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015134770A (ru) | Композиция, содержащая инкапсулированный антагомир | |
| McDermott et al. | The therapeutic potential of microRNAs: disease modulators and drug targets | |
| Sethi et al. | Regulating miRNA by natural agents as a new strategy for cancer treatment | |
| Park et al. | Antisense inhibition of microRNA-21 or-221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma | |
| CN104053775B (zh) | 用于治疗缺血性损伤的化合物 | |
| Hernando | microRNAs and cancer: role in tumorigenesis, patient classification and therapy | |
| JP2013514372A5 (enExample) | ||
| JP2015521626A5 (enExample) | ||
| HRP20201200T1 (hr) | OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK | |
| BRPI0811170B8 (pt) | oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila | |
| HRP20220379T1 (hr) | Antisense oligonukleotidi korisni u liječenju pompeove bolesti | |
| MX2013005875A (es) | Inhibidores de microarn que comprenden nucleotidos bloqueados. | |
| Ishimoto et al. | Current perspectives toward the identification of key players in gastric cancer micro RNA dysregulation | |
| WO2013157010A1 (en) | Methods and compositions for rnai-based cancer treatment | |
| EA201590070A1 (ru) | ИНГИБИТОРЫ МИКРОРНК СЕМЕЙСТВА miR-15 | |
| CN108350456A (zh) | 治疗性寡核苷酸 | |
| Mocellin et al. | Oncomirs: from tumor biology to molecularly targeted anticancer strategies | |
| JP2017527775A5 (enExample) | ||
| ES2664759T3 (es) | Enfoque basado en microARN para el tratamiento del mesotelioma pleural maligno | |
| WO2010055148A3 (en) | Dosage of oligonucleotides suitable for the treatment of tumors | |
| JP2020512819A (ja) | 骨量減少または筋機能低下に関連する病的状態を治療する際に使用するためのマイクロｒｎａ１９ａ／１９ｂ | |
| 樫山和也 | miR-196a downregulation increases the expression of type I and III collagens in keloid fibroblasts | |
| Angelica Cortez et al. | microRNAs in Cancer: From Bench to Bedside | |
| Ling et al. | MicroRNAs as Drugs and Drug Targets in Cancer |